The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma ( NHL ) therapy market over the…
Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL)…
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia…
Antibody drug conjugates (ADCs) are a class of drug therapies that combine the targeting abilities of monoclonal antibodies with the cancer-killing activities of cytotoxic agents. ADCs can…
The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig…
Recent and upcoming marketing authorizations and label expansions are increasing the therapy options for non-Hodgkin’s lymphoma (NHL). Despite a flourishing treatment armamentarium, tightening…
In China, multiple myeloma treatment is centered on the use of three major agents—Janssen’s Velcade (bortezomib), Celgene’s Revlimid (lenalidomide), and thalidomide—while the treatment for…
Multiple label expansions of premium-priced agents and the launch of seven novel therapies will fuel the significant growth of the NHL market over the ten-year forecast period. The biosimilar…
Non-Hodgkin’s lymphoma represents a segment of heterogeneous disease with multiple indolent and aggressive subtypes. The antineoplastic treatment rate in B-cell NHL patients is typically high…
LaunchTrends: Venclexta (Wave 1) is the first in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic…
The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the…
Last Updated 2 November 2015 Fueled by multiple label expansions of premium-priced agents and the launch of four novel therapies, the NHL market will experience significant growth over the ten-year…